X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs IPCA LABS - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE IPCA LABS CADILA HEALTHCARE/
IPCA LABS
 
P/E (TTM) x 16.8 29.2 57.6% View Chart
P/BV x 4.0 3.5 115.0% View Chart
Dividend Yield % 1.0 0.1 758.8%  

Financials

 CADILA HEALTHCARE   IPCA LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
IPCA LABS
Mar-18
CADILA HEALTHCARE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs558695 80.2%   
Low Rs362400 90.4%   
Sales per share (Unadj.) Rs116.3260.2 44.7%  
Earnings per share (Unadj.) Rs17.919.0 94.2%  
Cash flow per share (Unadj.) Rs23.133.1 70.0%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.80.2 417.0%  
Book value per share (Unadj.) Rs85.4213.0 40.1%  
Shares outstanding (eoy) m1,023.74126.20 811.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.1 187.8%   
Avg P/E ratio x25.728.9 89.1%  
P/CF ratio (eoy) x19.916.6 120.0%  
Price / Book Value ratio x5.42.6 209.4%  
Dividend payout %19.65.3 371.6%   
Avg Mkt Cap Rs m470,66469,120 680.9%   
No. of employees `00011.813.3 89.2%   
Total wages/salary Rs m18,5457,359 252.0%   
Avg. sales/employee Rs Th10,072.72,477.4 406.6%   
Avg. wages/employee Rs Th1,569.1555.2 282.6%   
Avg. net profit/employee Rs Th1,547.7180.6 856.8%   
INCOME DATA
Net Sales Rs m119,04932,836 362.6%  
Other income Rs m1,132418 270.8%   
Total revenues Rs m120,18133,254 361.4%   
Gross profit Rs m28,4754,505 632.1%  
Depreciation Rs m5,3881,777 303.2%   
Interest Rs m911240 379.3%   
Profit before tax Rs m23,3082,905 802.3%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644511 1,104.3%   
Profit after tax Rs m18,2922,394 764.0%  
Gross profit margin %23.913.7 174.3%  
Effective tax rate %24.217.6 137.6%   
Net profit margin %15.47.3 210.7%  
BALANCE SHEET DATA
Current assets Rs m82,00519,455 421.5%   
Current liabilities Rs m60,72010,076 602.6%   
Net working cap to sales %17.928.6 62.6%  
Current ratio x1.41.9 69.9%  
Inventory Days Days7398 74.7%  
Debtors Days Days9867 146.8%  
Net fixed assets Rs m83,70320,260 413.2%   
Share capital Rs m1,024252 405.7%   
"Free" reserves Rs m86,42126,633 324.5%   
Net worth Rs m87,44526,886 325.2%   
Long term debt Rs m25,5512,340 1,091.9%   
Total assets Rs m180,65341,173 438.8%  
Interest coverage x26.613.1 203.0%   
Debt to equity ratio x0.30.1 335.7%  
Sales to assets ratio x0.70.8 82.6%   
Return on assets %10.66.4 166.1%  
Return on equity %20.98.9 234.9%  
Return on capital %22.010.8 204.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m42,68315,642 272.9%   
Fx outflow Rs m11,2424,884 230.2%   
Net fx Rs m31,44110,759 292.2%   
CASH FLOW
From Operations Rs m9,1933,411 269.5%  
From Investments Rs m-9,737-1,354 719.1%  
From Financial Activity Rs m515-1,304 -39.5%  
Net Cashflow Rs m-29753 -3.9%  

Share Holding

Indian Promoters % 74.8 45.9 163.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.4 72.8%  
FIIs % 5.9 25.3 23.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.4 63.2%  
Shareholders   44,069 36,892 119.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 14, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS